
Opioid Overdose Trends and the Role of Community Pharmacists


James J. Gasper, PharmD, BCPP
Pharmacy Benefits Division
Department of Health Care Services
james.gasper@dhcs.ca.gov

Drug Overdose Deaths in the U.S.




Warner M, et al. Drug Poisoning Deaths in the United States 1980-2008. National Center for Health Statistics 2011;81:1-8. Jones CM. Prescription Drug Abuse and Overdose in the United States. Presented at Third Party Payer and PDMP Meeting 2012. MMWR January 1, 2016.

Overdose Deaths: Prescription Opioids



Source: National Center for Health Statistics, CDC Wonder


Overdose Deaths: Heroin




Source: National Center for Health Statistics, CDC Wonder

Overdose Deaths in California

5 year totals: 2008-2012 (All opioids, All intents) rate per 100,000



Source: CDPH Vital Statistics Death Statistical Master File Prepared by CDPH, Safe and Active Communities Branch Report generated from http://epicenter.cdph.ca.gov on Dec 19, 2014



California's Gap in Treatment Access

Past Year Opioid Abuse or Dependence

Rate per 1000 residents

7.6

Buprenorphine Capacity

3.4


Methadone Capacity

1.3

Gap = 2.9 per 1,000 or > 100,000

Jones et al. Am J Public Health 2015;105:e55-63 2014 census of licensed slots reported by CA Department of Health Care services

Treatment Saves Lives



The Solutions

Safe prescribing practices

Naloxone distribution

Access to treatment for opioid addiction

Naloxone Pharmacy Access Timeline

September 2014 AB 1535 signed

January 2015 4052.01 implemented

April 2015 emergency regulations

Making Naloxone Happen

Training availability

Pharmacy adoption of policies and marketing of naloxone access

Proactive patient selection by pharmacists

Making Naloxone Happen

Affordable commercial naloxone product

Clarity on who is the "prescriber on record"

 Third party reimbursement for pharmacist NPI's

Increasing Access to Treatment

Active participation in buprenorphine treatment by pharmacists

 Need to partner with local prescribers for collaborative care of buprenorphine patients

Increasing Access to Treatment

 Willingness of pharmacies and pharmacists to become remote methadone dispensaries for OBOT methadone programs

 Particularly needed in rural areas where methadone clinics do not exist